18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

February 6, 2028

Study Completion Date

February 6, 2028

Conditions
Metastatic Prostate CancerProstatic NeoplasmsProstate CancerProstatic CancerProstate Neoplasms
Interventions
DRUG

18F-NaF

Baseline IV followed by PET/CT IMAGING

DRUG

18F-DCFPyL

Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.

DRUG

18F-FDG

Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH